Baseline status | Control subjects (n = 157) | SMC/MCI (n = 396) | AD (n = 124) |
---|---|---|---|
Male sex | 77 (49%) | 204 (52%) | 72 (58%) |
Age, years | 74 ± 6 | 72 ± 7a | 75 ± 8 |
ApoE4 carriers | 42 (27%) | 186 (47%)b | 82 (66%)c |
Baseline cognition | |||
GDS | 0.7 ± 1.1 | 1.4 ± 1.4b | 1.7 ± 14c |
MMSE | 29 ± 1 | 27 ± 3b | 23 ± 2c |
CDR 0 | 157 (100%) | 96 (24%)b | 0c |
CDR 0.5 | 0 | 299 (76%)a | 53 (43%)c |
CDR ≥1 | 0 | 1 (0.3%) | 71 (57%)c |
ADAS-cog | 9 ± 5 | 16 ± 10b | 31 ± 8c |
Baseline CSF | |||
Aβ1–42, ng/L | 196 ± 50 | 175 ± 53b | 137 ± 38c |
Tau, ng/L | 67 ± 34 | 88 ± 54b | 133 ± 65c |
p-Tau181, ng/L | 33 ± 16 | 43 ± 26b | 60 ± 35c |
p-Tau181/Aβ1–42 | 0.19 ± 0.13 | 0.29 ± 0.24b | 0.48 ± 0.32c |